感染症と治療ジャーナル

抽象的な

Management of Covid-19 in Morocco: What Protocol and What Are the Factors Associated With Early Viral Clearance?

K Ennibi, Z Kasmy, A Reggad, A Laatiris, Y Aadi, A Nachite, Y Moutmir and Y Akhouad

Context: Morocco has adopted the protocol combining hydroxychloroquine or chloroquine with azithromycin to treat patients with
COVID-19, mainly based on Chinese studies and those of the IHU Mediterranee team in Marseille.
The objective of this study is to assess the effectiveness of this association in a Moroccan population.
Methods: We conducted a prospective descriptive analytical study at the Center of virology, infectious and tropical diseases to
assess the efficacy of hydroxychloroquine associated with azithromycin for the treatment of patients with COVID-19.
All patients hospitalized at the Center between March 16, 2020 and June 16, 2020 was included in this study with a positive RT-PCR
result for SARS-CoV-2.
Results: 186 patients were hospitalized during this period meeting the inclusion criteria. All patients benefited from the combination
of hydroxychloroquine and azithromycin. We studied the clinical, biological and CT parameters that could be associated with early viral
clearance with a negative RT-PCR on D6 and D8.
The average age at diagnosis is 36.29 ± 11.56 years. 182 patients (97.84%) were cured after 10 days of treatment. 51 patients
(27.41%) had a viral clearance on D6 and D8. In the univariate analysis, the absence of lymphopenia was significantly associated with
early viral clearance (p=0.036). In the multivariate analysis, young age less than 40 years and a normal Lactate Dehydrogenase level
were associated with early viral clearance (p=0.014 and p=0.016).
Conclusion: Our study did not show early viral clearance in patients treated with the combination of hydroxychloroquine and
azithromycin, although clinical healing has been achieved in the majority of patients.